Xarelto lawsuit settlement amounts
GET JUSTICE NOW
Finally, there’s justice for many of the 25,000 lawsuits filed against Bayer AG and Johnson & Johnson. They have agreed to settle and pay over $775 million, and more victims can join in. This is a huge win and opens the flood gates for new claims. Big Pharma is now being held accountable for the dangerous drug Xarelto.
If you have found this page, there’s a good chance that you or a loved one has experienced some of the negative side effects of the drug Xarelto, and now you’re looking for options and information on how to proceed. If so, you’re in the right place.
Call 888-574-3737 to speak with a Lawyer.
Welcome to the Class Action Legal Center Xarelto information page. Here, you will find valuable insight and information on the medical conditions caused by the drug, your legal rights to recover damages or compensation, and the resources available to you in pursuit of that recovery. We hope that you will use this page to answer some of your general questions and to contact us with your more specific questions and concerns.
There are currently over 25,000 lawsuits pending before the court as of this writing, so clearly if you have experienced side effects of this drug, you aren’t alone. Obviously, the circumstances, details, and potential settlements in each case differ based on specifics. This is where the legal pros at Class Action Legal Center can help. We specialize in evaluating the individual circumstances of your case and connecting you with the best attorneys and firms in the nation to ensure you get the justice to which you are entitled. Our clients have already recovered hundreds of millions in damages and settlements in similar cases.
With this drug, what is alleged in many of the pending suits is that the drug makers and marketers were well aware of the high risk involved, and did not adequately disclose that risk to doctors and patients. If proven, this claim would make the drug maker legally liable for damages to anyone who suffered the ill effects of the drug. While this claim is hotly denied by the drugs’ manufacturers, it is easy to see how this could happen. Billions of dollars in annual sales are at stake, and Xarelto remains a popular and heavily prescribed medication. Time after time, consumers have seen their safety traded for higher Big Pharma profit margins. Many experienced attorneys believe that it has happened again here. Let the Class Action Law Center connect you with one of those skilled and successful attorneys.
Xarelto is the name brand of the drug Rivaroxaban. It was developed in 2008 and approved by the FDA in 2011 by Bayer and is marketed in the US by Jassen Pharmaceutica. The drug is a blood thinner and anticoagulant and is used to treat and prevent averse blood clotting which can lead to stroke (deep vein thrombosis, pulmonary embolism, or the clotting effect of atrial fibrillation.) It is also commonly used after knee or hip surgeries, again, to prevent averse blood clotting.
Unfortunately, this drug has some quite severe side effects. People using it have suffered from gastrointestinal, cranial, and retinal hemorrhaging. Worse, and unlike other anticoagulants, there is no way to turn off the anticoagulant effect of the drug, as there is with other anticoagulants, in an emergency. Doctors have seen patients bleed to death and had no way to stop it, due to this critical and potentially deadly shortcoming.
The number of prescription drugs and medical devices on the market is increasing daily, making it nearly impossible for consumers to keep up with the ever-expanding number of treatment options and their potential side effects. It is for that reason that the US Food and Drug Administration (FDA) is entrusted with the essential task of protecting the public from unsafe medical products.
2019 we partnered with The Xarelto Class Action Claims Center. We believe they are going to get the largest Xarelto lawsuit settlement amounts; the group of attorneys they work with are outstanding.
The Federal Drug Agency has given Merck the thumbs up for 'Keytruda' (pembrolizumab), an immuno-oncology drug, to be used for patients with metastatic non-small cell lung cancer whose tumors have high PD-L1 expression, with no EGFR or ALK genomic tumor aberrations. This makes Keytruda the only anti-PD-1 therapy to be approved in the first line treatment setting for these patients. This announcement came as a bit of a shock, with the approval coming almost two months earlier than the...
Prof. Saverio Stranges, a visiting academic of the University of Warwick Medical School, United Kingdom as well as the scientific director of the department of population Health at Luxembourg Institute of Health, alongside his colleagues, have released what will from now on be known as the most...
The name quinoa, pronounced ‘keen wah’ seems to be everywhere at the moment, but I for one had no idea what anyone was talking about! Is it rice? Couscous? Flour? All I knew was it was some kind of grain that is supposed to be very high in protein, so I did some investigating and was amazed...
